GLP1R and hypertensive disorder: In contrast, comparisons between the non GLP-1 therapy cohort and the GLP-1 targeting agents cohort revealed no significant differences in age (median: 57.2 vs. 60.0 years, p=0.49), BMI (median: 30.8 vs. 34.9 kg/m2, p=0.16) or hypertension (65.3% vs. 84.6%; p=0.065).